Physician profile
Abraham Cheong
NPI 1285624882
$18,194.08
in general payments reported to CMS, 2019-2025
79 companies · $2,993 in 2025
The $2,993 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $1,650 · 2021: $2,964 · 2022: $2,839 · 2023: $2,938 · 2024: $3,258 · 2025: $2,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,073 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,072.67 |
| Education | $117.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,813.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,144.98 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $1,045.88 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $1,041.46 | 2019-2025 | |
| Janssen Biotech, INC. | $855.97 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $834.77 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Amgen INC. | $765.91 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Seagen INC. | $553.03 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Genentech USA, INC. | $539.13 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Genzyme Corporation | $506.53 | 2019-2025 | |
| Incyte Corporation | $457.44 | 2019-2025 | Zynyz, Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $448.64 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $429.11 | 2019-2025 | |
| Eisai INC. | $423.80 | 2020-2025 | |
| Exelixis INC. | $381.15 | 2020-2025 | Cabometyx |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $364.81 | 2019-2025 | Libtayo, Lynozyfic |
| Astellas Pharma US INC | $354.56 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Celgene Corporation | $336.92 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Puma Biotechnology, INC. | $335.44 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $327.86 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Glaxosmithkline, LLC. | $284.83 | 2022-2025 | Ojjaara, Shingrix, Zejula |
| Daiichi Sankyo INC. | $278.65 | 2019-2025 | Enhertu |
| Gilead Sciences, INC. | $236.40 | 2022-2025 | Trodelvy |
| Octapharma USA, INC. | $232.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.01 | 2019-2025 | Gilotrif |
| Taiho Oncology, INC. | $231.52 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $228.39 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Lilly USA, LLC | $206.08 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Kite Pharma, INC. | $196.76 | 2021-2025 | Yescarta |
| Abbvie INC. | $183.36 | 2019-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $170.52 | 2020-2025 | Ultomiris |
| Morphosys, US INC. | $128.38 | 2021-2023 | Monjuvi |
| Emd Serono, INC. | $128.02 | 2022-2025 | Bavencio |
| Sobi, INC | $124.42 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $123.24 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $119.93 | 2020-2023 | Imbruvica |
| Myovant Sciences INC. | $118.14 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $116.07 | 2023-2025 | Orgovyx |
| Tersera Therapeutics LLC | $115.28 | 2023-2025 | Zoladex |
| Janssen Pharmaceuticals, INC | $113.18 | 2019-2024 | Xarelto |
| Karyopharm Therapeutics INC. | $109.03 | 2020-2025 | Xpovio |
| Coherus Oncology, INC. | $105.15 | 2020-2022 | |
| Beigene USA, INC. | $104.52 | 2023-2025 | Brukinsa |
| Csl Behring | $96.92 | 2023-2024 | Hizentra |
| Array Biopharma INC | $72.13 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $72.06 | 2019-2024 | Onivyde |
| Cti Biopharma Corp. | $69.80 | 2023 | Vonjo |
| Teva Pharmaceuticals USA, INC. | $58.52 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $57.84 | 2019-2021 | |
| Boston Scientific Corporation | $55.75 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Deciphera Pharmaceuticals INC. | $54.37 | 2021-2022 | |
| Geron Corporation | $53.13 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $47.92 | 2021-2025 | |
| Beone Medicines USA, INC. | $44.07 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $43.91 | 2025 | |
| Dova Pharmaceuticals | $43.48 | 2020-2021 | |
| Immunocore Limited | $41.66 | 2025 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $40.50 | 2021-2023 | Precisetumor |
| Acrotech Biopharma INC. | $36.51 | 2022-2024 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $33.04 | 2022-2023 | Fotivda |
| Mirati Therapeutics, INC. | $32.85 | 2023 | Krazati |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.83 | 2021 | |
| Recordati_rare_diseases_inc. | $32.48 | 2023-2025 | Enjaymo, Sylvant |
| Caris Mpi, INC. | $32.39 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $28.90 | 2023 | |
| Legend Biotech USA INC. | $25.63 | 2025 | Carvykti |
| Clovis Oncology, INC. | $24.78 | 2019-2020 | |
| Stemline Therapeutics INC. | $24.21 | 2023 | Orserdu |
| Tempus Ai, INC | $22.51 | 2025 | Xt Cdx |
| Iovance Biotherapeutics, INC. | $21.59 | 2025 | Amtagvi |
| Pharmaessentia USA Corporation | $20.02 | 2022 | |
| Immunogen, INC. | $19.78 | 2024 | Elahere |
| Blueprint Medicines Corporation | $18.44 | 2022 | |
| Argenx US, INC. | $18.44 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Alnylam Pharmaceuticals INC. | $17.28 | 2021 | |
| Ge Healthcare | $17.01 | 2022 | |
| Tactile Systems Technology INC | $15.51 | 2025 | Flexitouch Plus, Nimbl |
| Sanofi-Aventis U.S. LLC | $11.35 | 2019 | |
| Secura Bio, INC. | $9.52 | 2020 |
Drugs and devices associated with these payments
Xtandi $460Keytruda $422Orgovyx $388Imfinzi $312Talzenna $303Rybrevant $285Kisqali $249Padcev $242Lenvima $240Opdivo $237Enhertu $228Adcetris $224Zepzelca $216Elrexfio $216Opdualag $208Reblozyl $207Tukysa $193Bosulif $187Vonjo $180Cabometyx $178Pluvicto $176Calquence $174Scemblix $165Jaypirca $153Verzenio $153Libtayo $152Stivarga $151Ojjaara $149Brukinsa $149Welireg $148Lonsurf $148Inqovi $148Rezlidhia $148Tavalisse $148Fruzaqla $131Polivy $130Ibrance $126Vitrakvi $123Venclexta $119Zoladex $115Sarclisa $111Erleada $103Hizentra $96.92Yescarta $92.03Inlyta $89.12Tibsovo $87.59Darzalex $86.57Lynparza $86.28Besponsa $82.46Gilotrif $81.98Krazati $81.77Akeega $79.10Balversa $79.10Monjuvi $77.79Trodelvy $76.24Lunsumio $72.98Braftovi $72.13Nerlynx $70.42Nubeqa $65.83Piqray $61.26Promacta $59.48Columvi $56.21Mektovi $56.16Gavreto $54.78Fabhalta $53.71Tasigna $53.68Rytelo $53.13Xpovio $52.73Lorbrena $52.60Ultomiris $51.86Imbruvica $51.00Alunbrig $48.11Shingrix $45.40Vyloy $44.99Retevmo $44.67Zejula $44.01Jemperli $44.01Zynlonta $43.91Lynozyfic $42.09Kimmtrak $41.66Jevtana $41.13Bavencio $38.70Tecvayli $34.66Mi Cancer Seek $32.39Talvey $30.19Xarelto $29.29Eligard $28.90Wavewriter Alpha Prime 16 $28.56Kyprolis $28.32Odomzo $28.31Yonsa $28.31Carvykti $25.63Iclusig $25.39Pomalyst $24.66Orserdu $24.21Keytruda Qlex $24.11Xalkori $24.04Beleodaq $22.65Xt Cdx $22.51Cuvitru $21.99
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Cheong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.